【24h】

Amiodarone-Induced Thyroid Dysfunction: A Clinical Update

机译:胺碘酮诱导的甲状腺功能障碍:临床更新

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Amiodarone is one of the most commonly prescribed antiarrhythmic agents in clinical practice owing to its efficacy, even with high toxicity profile. The high iodine content and the prolonged biological half-life of the drug can result in thyroid dysfunction in a high proportion of patients treated with amiodarone even after cessation of amiodarone. Both hypothyroidism and hyperthyroidism are common side effects that mandate regular monitoring of patients with thyroid function tests. Amiodarone-induced hypothyroidism (AIH) is diagnosed and managed in the same way as a usual case of hypothyroidism. However, differential diagnosis and clinical management of amiodarone-induced thyrotoxicosis (AIT) subtypes can be challenging. With the aid of a case snippet, we update the current evidence for the diagnostic work up and management of patients with amiodarone-induced thyroid dysfunction in this article.
机译:胺碘酮是由于其疗效,即使具有高毒性概况,也是由于其疗效而在临床实践中最常见的抗心律失常药剂之一。 即使在胺碘酮停止后,药物的高碘含量和延长的药物生物半衰期可能导致用胺碘酮治疗的高比例患者导致甲状腺功能障碍。 甲状腺功能减退症和甲状腺功能亢进症均为常见的副作用,其授权定期监测甲状腺功能试验的患者。 胺碘酮诱导的甲状腺功能减退症(AIH)被诊断和管理,以与甲状腺功能亢进的通常情况相同。 然而,胺碘酮诱导的甲状腺毒性症(AIT)亚型的鉴别诊断和临床管理可能是挑战性的。 借助案例片段,我们更新目前的证据,以便在本文中对胺碘酮诱导的甲状腺功能障碍患者进行诊断处理和管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号